Mankind Pharma Reports 10.7% Decline in Q4 Net Profit

Mankind Pharma reported on Wednesday a 10.7% year-over-year fall in net profit for the quarter ended March 2025 (Q4 FY25), at Rs 420.8 crore versus Rs 471.2 crore in the same quarter last year.

This decline in profitability came even as the company posted strong revenue growth and continued growth in its chronic therapy and consumer healthcare business segments.

Mankind's revenue for the March quarter rose 27.1% to Rs 3,079.4 crore, driven by consistent increments in the treatments for chronic diseases, higher consumer health product demand, and the acquisition of Bharat Serums and Vaccines (BSV) last month, which boosted its presence in gynecology and specialized treatments.

Even though EBITDA increased by 16.5% to Rs 683.2 crore in the quarter, the EBITDA margin of the company decreased to 22.2% from 24.2% last year. The dip in margins was mainly due to integration-related cost and regulatory challenges in the segment of acute therapy.

For the financial year FY25, Mankind Pharma reported total revenues at Rs 12,207 crore, up 19% from FY24.

Domestic sales contributed Rs 10,675 crore, while exports witnessed a steep rise of 88% to Rs 1,532 crore.

Adjusted EBITDA margin of the company in the year was 25.9%.

Rajeev Juneja, Vice Chairman and Managing Director, Mankind Pharma, emphasized that the fourth quarter reflected continued strong performance in chronic therapies, increasing momentum in consumer health business, and smooth integration progress with BSV.

He termed FY25 as milestone year for the company that has provided solid foundation for long-term, sustainable growth.

Mankind Pharma also continued to be India's number one pharma company by prescription volume for eighth year in a row.

Its consumer health businesses such as Manforce, Gas-O-Fast, and HealthOK reported double-digit growth during the financial year.

Mankind Pharma shares closed slightly lower at Rs 2,533.05 on the Bombay Stock Exchange (BSE), down 0.69%.